Today is Day 2 of the Indogulf Cropsciences IPO, which opened yesterday, 26 June 2025. The bidding window is scheduled to close on 30 June 2025.
Indogulf Cropsciences IPO is a book-building issue of ₹200 crores, consisting of a fresh issue of ₹160 crores and an offer for sale of ₹40 crores. The price band is set between ₹105 and ₹111 per share.
The basis of allotment will be finalised by July 1, 2025, and the tentative listing date on BSE and NSE is July 3, 2025.
The book running lead manager for the IPO is Systematix Corporate Services Limited, while Bigshare Services Pvt Ltd is the registrar for the issue.
[27-June-2025 10:51:00 AM]
Investor Category |
Subscription (Times) |
Qualified Institutional Buyers(QIBs) |
0.05 |
Non-Institutional Investors |
0.41 |
Retail Individual Investors(RIIs) |
0.97 |
Employees |
0.08 |
Total |
0.56 |
Click here to explore other Upcoming IPOs
[26-June-2025 5:00:00 PM]
Investor Category |
Subscription (Times) |
Qualified Institutional Buyers(QIBs) |
0.05 |
Non-Institutional Investors |
0.27 |
Retail Individual Investors(RIIs) |
0.69 |
Employees |
0.05 |
Total |
0.40 |
Read More: Indogulf Cropsciences IPO Day 1 Subscription Status
The net proceeds from the fresh will be used to:
As of 27 June 2025, Indogulf Cropsciences' IPO's GMP stood at ₹9. The estimated listing gain is ₹120, i.e., an 8.11% gain per share over the upper price band.
Source: Business Standard Report dated 27 June, 2025
Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market.
Indogulf Cropsciences manufactures crop protection products, plant nutrients and biologicals.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here